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Abstract
Epidermal growth factor receptor (EGFR) signalling is initiated by the release of EGFR-ligands from membrane-anchored
precursors, a process termed ectodomain shedding. This proteolytic event, mainly executed by A Disintegrin And
Metalloproteases (ADAMs), is regulated by a number of signal transduction pathways, most notably those involving protein
kinase C (PKC). However, the molecular mechanisms of PKC-dependent ectodomain shedding of EGFR-ligands, including
the involvement of specific PKC isoforms and possible functional redundancy, are poorly understood. To address this issue,
we employed a cell-based system of PMA-induced PKC activation coupled with shedding of heparin binding (HB)-EGF. In
agreement with previous studies, we demonstrated that PMA triggers a rapid ADAM17-mediated release of HB-EGF.
However, PMA-treatment also results in a protease-independent loss of cell surface HB-EGF. We identified PKCa as the key
participant in the activation of ADAM17 and suggest that it acts in parallel with a pathway linking PKCd and ERK activity.
While PKCa specifically regulated PMA-induced shedding, PKCd and ERK influenced both constitutive and inducible
shedding by apparently affecting the level of HB-EGF on the cell surface. Together, these findings indicate the existence of
multiple modes of regulation controlling EGFR-ligand availability and subsequent EGFR signal transduction.
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Introduction
The epidermal growth factor receptor (EGFR) tyrosine kinase
has been at the forefront of studies of signal transduction events
that determine cell fate and behaviour. Ligand binding and EGFR
activation triggers intracellular signalling pathways stimulating cell
proliferation, motility, and survival—key processes in tumour
growth and dissemination [1]. In human carcinomas, excessive
EGFR signalling is associated with a more aggressive phenotype
and decreased patient survival, and interference with EGFR
activation is the basis for a number of therapies [2].
Signalling through the EGFR is initiated by the release of mature
receptor ligands from their membrane-anchored precursor forms, a
process termed ectodomain shedding [3]. Metalloproteases of the
ADAM (A Disintegrin And Metalloprotease) family are principally
responsible for the shedding of EGFR-ligands, which include
epidermal growth factor (EGF), heparin-binding (HB)-EGF, trans-
forminggrowthfactor(TGF)a,amphiregulin,betacellulin,epiregulin,
and neuregulins [3,4]. ADAMs are type I transmembrane glycopro-
teins, comprising extracellular pro, metalloprotease, disintegrin, and
cysteine-rich domains, as well as a transmembrane domain and a
cytoplasmic tail [3,5,6]. Previous studies identified ADAM10 and -17
as the major EGFR-ligand sheddases, however, several other
catalytically active ADAMs (ADAM8, -9, -12, and -19) appear to
contribute to ligand cleavage under certain circumstances [7,8].
Like EGFR, some ADAMs are upregulated in human
carcinomas and their expression correlates with tumour stage
[9,10,11]. Inhibition of ADAM17-mediated shedding reduces the
growth of tumor xenografts in mice [12], and ADAM9 and -12
enhance tumour progression in transgenic mouse models of
prostate and breast cancer [13,14,15]. Moreover, aberrant release
of EGFR-ligands, such as TGFa and HB-EGF leads to malignant
growth of carcinoma cells [10,12,16]. Hence, a key question in
EGFR signalling in cancer is how ADAM protease activity and
subsequent shedding of EGFR-ligands is regulated.
While some constitutive EGFR-ligand shedding is observed, the
upregulation of ectodomain shedding by phorbol esters (phorbol 12-
myristate 13-acetate, PMA) is considered to be a critical hallmark of
ADAM-mediated shedding [17]. In addition, ectodomain shedding
can be regulated by other stimuli, including calcium ionophores,
calmodulin inhibitors and stimulation of G protein-coupled receptors
(GPCR) or the mitogen-activated protein (MAP) kinase pathway
[3,18]. PMA-induced shedding is known to depend on protein kinase
C (PKC) activity, and generally, ADAM17 seems to be the major
PMA-responsive sheddase [7,19]. PKC isoforms are divided into
three structurally and functionally distinct subgroups. The conven-
tional, PKC isoforms (PKCa,P K C b,a n dP K C c) are diacylglycerol
(DAG) sensitive and Ca
2+ responsive, the novel PKC isoforms
(PKCd,P K C e,P K C g and PKCh) are DAG sensitive, but Ca
2+
insensitive, whereas the atypical PKC isoforms (PKCf and PKCi/l)
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2+ [20]. The molecular
mechanisms of PKC-dependent ADAM protease activation remain
elusive and insight into the specific contribution and potential
functional redundancy of individual PKC isoforms is currently
lacking.
Using PMA-induced ectodomain shedding of HB-EGF in
human HT1080 fibrosarcoma cells as a model system, we
demonstrate here a complex mode of regulation, involving
ADAM17 protease activation as well as an apparent transport of
substrate to and from the cell surface. Inhibition of ADAM17
protease activity completely prevents the induced proteolytic
release of HB-EGF, yet some ADAM17-independent loss of cell
surface HB-EGF is still observed. The non-proteolytic loss of cell
surface HB-EGF could suggest that in addition to activation of
ADAM17, PMA-treatment may induce some degree of HB-EGF
internalization. Interestingly, while inactivation of PKCa, PKCd
or the ERK MAPK pathway alone, each lead to a statistically
significant, but incomplete reduction in PMA-induced HB-EGF
shedding, combined inactivation of PKCa together with either
PKCd or MEK inhibition results in a synergistic effect and total
blockage of ADAM17-dependent cleavage. This suggests that two
separate signalling pathways may contribute to the stimulated
release of bioactive HB-EGF—one acting through PKCa, and the
other connecting PKCd and ERK activation.
Results
Phorbol ester-induced ectodomain shedding of HB-EGF
is ADAM17-dependent
To study the molecular mechanisms of PKC-mediated ADAM
protease activation, we used a previously reported cell-based
model system for PMA-induced ectodomain shedding of HB-EGF
[21]. Specifically, a fusion protein of proHB-EGF with placental
alkaline phosphatase inserted in the extracellular domain (AP-HB-
EGF) was stably expressed in the HT1080 human fibrosarcoma
cell line. Western blot analysis of extracts from untreated cells
showed a band at approximately 100 kDa corresponding to the
expected size of intact, unmodified (i.e. intracellular) AP-HB-EGF,
as well as a less abundant band migrating slightly slower, which
appears to be the glycosylated AP-HB-EGF, on the plasma
membrane (Figure 1A). PMA-treatment resulted in the disap-
pearance of the glycosylated form of AP-HB-EGF with little or no
effect on faster migrating non-glycosylated AP-HB-EGF, indicat-
ing that only substrate molecules that had completed transit
through the trans-Golgi were cleaved (Figure 1A).
The PMA-induced shedding of HB-EGF can be assessed
quantitatively using two different experimental approaches—by
measuring the amount of released alkaline phosphatase activity
spectrophotometrically (Figure 1B), or by measuring the residual
cell surface fluorescence intensity per cell after immuno-staining of
AP-HB-EGF (Figure 1C). The two assays complement each other
by distinguishing changes in cell surface cleavage from other
changes in the amount of AP-HB-EGF at the plasma membrane.
Comparing the data obtained by the two assays, in untreated cells a
low basal/constitutive release to the conditioned cell media was
observed and high levels of substrate could be detected on the cell
surface. PMA-treatment triggers a rapid release of AP-HB-EGF to
the conditioned medium, where it accumulates over a 60 min time
period (Figure 1B). From the amount of residual substrate on the
cell surface, it is clear that PMA-treatment results in substantial loss
from the cell surface after 15 min, with near-complete depletion
after 30 min, at which point no further loss of substrate could be
detected (Figure 1C). The fact that alkaline phosphatase activity in
the conditioned medium continued to increase for up to 60 min
(Figure 1B), whereas no difference in cell surface levels was
observed, indicates that continuous transport of substrate to the
plasma membrane occurs, which is then immediately processed.
Previous loss-of-function studies demonstrated that at least in
mouse embryonic fibroblasts, ADAM17 is the PMA-responsive
sheddase of EGFR-ligands [7]. In order to investigate whether this
Figure 1. PMA-induced ectodomain shedding of HB-EGF from
the cell surface. A) Western blot analysis of total cell extracts from
HT1080 cells stably expressing alkaline phosphatase tagged HB-EGF
(AP-HB-EGF) or mock transfected controls after 30 min treatment with
400 nM PMA or DMSO control. a-Tubulin is used as an internal loading
control. B) AP-HB-EGF release measured as alkaline phosphatase activity
(absorbance at 405 nm) in conditioned media, and C) surface AP-HB-
EGF measured as cell surface fluorescence intensity per cell (FLU/cell) in
AP-HB-EGF expressing HT1080 cells after 15, 30, or 60 min treatment
with 400 nM PMA (white bars) or DMSO control (black bars). The graphs
show average values 6 standard error of the mean of triplicate
experiments. *p,0.05; **p,0.01, ***p,0.001 after one-way ANOVA
with Bonferroni’s post tests for multiple comparisons. Unless otherwise
indicated, the comparison is relative to the respective control.
doi:10.1371/journal.pone.0017168.g001
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fibrosarcoma cells, we first tested the effect of the small molecule
inhibitor TAPI-2 that, while being a non-specific inhibitor of many
ADAMs and some other metalloproteases, is a potent inhibitor of
ADAM17 protease activity. As shown in Figure 2A, TAPI-2
completely prevented the PMA-induced release of AP-HB-EGF
into the conditioned medium. By contrast, the PMA-induced loss
of cell surface substrate was only partially inhibited (Figure 2B),
suggesting that PMA triggers both ectodomain shedding and an
additional loss of cell surface HB-EGF. Next, we used the more
specific approach of siRNA-mediated ADAM17 knockdown to
examine the PMA-induced AP-HB-EGF shedding. As seen in
Figure 2C, similar to the effect of pharmacological ADAM17
protease inhibition, loss of ADAM17 expression caused an almost
complete block in the PMA response. Moreover, as for TAPI-2
treatment, ADAM17 knockdown did not completely block the
depletion of cell surface substrate (Figure 2D). As shown by
western blot analysis of total cell lysates (Figure 2C), a clear
reduction in ADAM17 expression was observed after 72hr siRNA-
mediated knockdown. The fact that a small stimulatory response
of PMA on HB-EGF shedding was still observed after ADAM17
knockdown, while TAPI-2 caused a complete block could be due
to the contribution of other ADAMs. However, knockdown of
ADAM17 in combination with knockdown of ADAM9 or
ADAM12, which have both been implicated in HB-EGF shedding
in other cells, caused no further reduction of the PMA response
(data not shown), suggesting that the residual HB-EGF shedding is
rather due to incomplete knockdown of ADAM17. Together,
these data confirm previous reports, showing that ADAM17 is the
key PMA-responsive HB-EGF sheddase. Moreover, since mea-
suring the amount of HB-EGF in the conditioned cell media as
well as on the cell surface allowed us to distinguish between loss of
cell surface substrate due to proteolysis from other changes in
substrate availability, the data indicates that 30 min of PMA-
treatment not only triggers ADAM17-mediated ectodomain
shedding, but also induces significant loss of cell surface HB-
EGF by other means, which is insensitive to protease inhibition.
PKCa and PKCd play different but cooperative functions
in PMA-induced HB-EGF shedding
In agreement with previous inhibitor studies demonstrating that
PMA-induced HB-EGF shedding is dependent on PKC activity
[22], the broad PKC inhibitor BIM1, which inhibits classical and
novel PKC isoforms, inhibited both PMA-induced HB-EGF
cleavage and cell surface depletion (Figure 3A, B). Yet, the
relative contribution of specific PKC isoforms and whether
additional downstream kinases are involved is not known. In
order to address these issues, we screened the InhibitorSelect
TM 96-
Well Protein Kinase Inhibitor Library I and II that each consists of 80
well-characterized, cell-permeable, potent and reversible protein
kinase inhibitors, the majority of which are ATP-competitive. A
complete list of all the inhibitors is shown in Table S1. Library I
targets kinases belonging to the group of tyrosine kinases, AGC
kinases (PKA, PKG, and PKC), tyrosine kinase-like kinases and
others, whereas library II comprise inhibitors against Cdk, MAP,
GSK3, and CLK kinases, Ca
2+/Calmodulin Dependent Protein
Kinases (CAMK), as well as some AGC kinases. The inhibitors
were each used at 1 mM and 10 mM concentrations and the effect
on PMA-induced HB-EGF shedding was determined by alkaline
phosphatase activity in the cell medium as well as by cell surface
alkaline phosphatase immuno-staining. BIM1 (2 mM) was used as
a positive control. Representative heat maps of cell surface
fluorescence intensity per cell for the two libraries screened at
1 mM concentrations are shown in Figure 3C and 3D. Tables 1
and 2 show the identified hits from library I and II, respectively,
based on a threshold of an inhibitory effect on PMA-induced
shedding of two standard deviations from vehicle-treated controls
(z-score $2) in at least one of the tested concentrations in one of
the two readouts. Table 3 summarizes the specificity of the kinase
inhibitors shown to inhibit HB-EGF shedding in both types of
assay. Interestingly, apart from two inhibitors (the Chk1/2/CDK
inhibitor SB218078 and the p38 MAP kinase 3 inhibitor
SB220025, of which the latter inhibited shedding only at high
concentrations), only known PKC inhibitors were identified. Based
on the known isoform-specificity of these PKC inhibitors, classical
PKC isoforms (PKCa in HT1080) and one or more novel PKC
isoforms appeared to be involved.
To identify specifically different PKC isoforms in PMA-induced
shedding of HB-EGF, we reduced the expression of endogenous
PKC isoforms, either individually or in combination, using siRNA.
The knockdown efficiency and specificity was verified by western
blot analysis (Figure 4A). While no effect of PKCe was observed,
knockdown of PKCa caused a statistically significant reduction in
the PMA-induced release of HB-EGF, which was also reflected in
slightly higher fluorescence intensity on the cell surface after
immuno-fluorescent staining (Figure 4B, C). Knockdown of
PKCd also caused a statistically significant inhibition of stimulated
HB-EGF shedding (Figure 4B). The decreased HB-EGF shedding
after PKCd knockdown may be due to a lower amount of substrate
available for shedding on the cell surface rather than a reduced
shedding activity, as shown by a lower cell surface fluorescence
intensityin untreated cells(Figure 4C). Interestingly, the combined
knockdown of PKCa and PKCd almost completely abolished
release of HB-EGF into the cell media upon PMA-treatment
(Figure 4B), whereas no further effect on initial cell surface
expression was observed when compared to PKCd knockdown by
itself (Figure 4C). In addition, similar to what was seen for
ADAM17 knockdown, an almost complete loss of HB-EGF
shedding was not reflected in a similar complete block of cell
surface removal, supporting the observation that PMA induces both
HB-EGF cleavage and additional loss of cell surface substrate.
Since PMA is known to activate a variety of signalling pathways,
with potentially different dose- and time-dependency, we examined
the effect of PKCaand PKCdknockdown on HB-EGF shedding after
15 and 30 min treatment with low or high concentrations of PMA. As
expected, PMA-induced HB-EGF shedding was both dose- and time-
dependent, showing a 5.5-fold induction after 30 min treatment with
400 nM PMA versus 2.4-fold after 30 min treatment with 25 nM
PMA, and 3.2-fold induction after 15 min treatment with 400 nM
PMA. No difference in the effect of PKCa and PKCd knockdown on
the PMA-induced change in shedding was observed at 15 versus
30 min PMA-treatment at a concentration of 400 nM (Figure 4D).
However, when treating the cells with a low concentration of PMA
( 2 5n M )f o r3 0m i n ,t h e r ew a so n l ya ne f f e c to fP K C a knockdown,
whereas PKCd knockdown alone or in combination with PKCa had
no effect on the fold PMA-induced change in AP-HB-EGF release
(Figure 4D). Thus, these data suggest that PKCaand PKCdregulate
PMA-induced HB-EGF shedding through separate pathways, with
PKCa acting in response to low concentrations of PMA by inducing
ADAM17 activation, and PKCd playing a role in both transport of
HB-EGF to the cell surface and ADAM17 activation after exposure to
higher concentrations of PMA.
PMA-induced PKCa activation and MEK-dependent ERK
phosphorylation regulate HB-EGF shedding in a
synergistic manner
The implication of multiple pathways in PMA-induced HB-
EGF shedding led us to examine the mitogen-activated protein
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essential for the PMA response [23,24]. In untreated HT1080
cells, relatively low levels of active MAP kinases ERK1/2 were
detected, but PMA-treatment caused a marked increase, as
demonstrated by western blot using antibodies against phosphor-
ylated ERK1/2 (Figure 5A). Moreover, this activation was
blocked with both the MEK inhibitor UO126 and the broad PKC
inhibitor BIM1 (Figure 5A). While no ERK or MEK inhibitors
were identified in the kinase inhibitor screen (Figure 3 and
Table 1), the MEK inhibitor UO126 had a small but statistically
significant inhibitory effect on PMA-induced HB-EGF shedding in
HT1080 cells (Figure 5B). Interestingly, combining MEK
inhibition with knockdown of PKCa fully prevented PMA-
induced shedding in what appears to be a synergistic manner,
whereas the combination of UO126 and PKCd knockdown was
not significantly different from PKCd knockdown alone
(Figure 5C). As shown by western blot analysis in Figure 5D,
efficient knockdown of both PKC isoforms was obtained.
Although BIM1 inhibition prevented the PMA-induced ERK
activation (Figure 5A), knockdown of PKCa, PKCd, the two
isoforms together, or PKCe did not affect levels of phosphorylated
ERK1/2, after either low or high concentrations of PMA and at
various times of treatment (Figure 5D and data not shown). In
addition, knockdown of ADAM17 had no effect (Figure S1),
indicating that ERK phosphorylation is a proximal effect of PMA
rather than being downstream of ADAM17-mediated HB-EGF
shedding and subsequent EGFR activation. Together, these
findings indicate that PMA-induced HB-EGF shedding acts
through at least two separate pathways – one relying on PKCa
and the other involving both PKCd and ERK activation.
Discussion
Increased ligand-induced EGFR activation is a frequent driving
force in carcinoma progression, and in many human tumours,
excessive shedding of one or more EGFR-ligands appears to be a
key contributing factor [10,25]. A characteristic feature of
ectodomain shedding is its stimulation by PMA-induced PKC
activation. PKC-mediated signalling pathways are implicated in
several cellular processes of importance in tumour progression,
including proliferation, survival, migration and invasion [26].
Thus, how PKC regulates EGFR-ligand release and subsequent
EGFR activation is of great interest. The findings reported here,
using PMA-induced PKC activation as the molecular trigger of
Figure 2. PMA-induced HB-EGF shedding is ADAM17-dependent. A) AP-HB-EGF release measured as alkaline phosphatase activity (OD
405 nm) in conditioned media and B) surface AP-HB-EGF measured as cell surface fluorescence intensity per cell (FLU/cell) in DMSO control-treated
(C; black bars) and 30 min, 400 nM PMA-treated (PMA; white bars) AP-HB-EGF expressing HT1080 cells treated with the ADAM17 inhibitor TAPI-2
(10 mM) or vehicle control. C, D) as in A and B respectively, except that cells were reverse transfected with control (C) or ADAM17 siRNAs for 72 h
before treatment. The insert shows western blot analysis of total cell extracts from cells used in C and D, demonstrating efficient siRNA-mediated
knockdown of pro and mature forms (arrows) of ADAM17. a-tubulin is used as an internal loading control. All graphs show average values 6 standard
error of the mean of at least three independent experiments each done in triplicate. *p,0.05; **p,0.01, ***p,0.001 after one-way analysis of
variance with Bonferroni’s post tests for multiple comparisons. Unless otherwise indicated the comparison is relative to the respective control.
doi:10.1371/journal.pone.0017168.g002
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regulation. First, two independent events are initiated by PMA –
one being ADAM17-mediated ectodomain shedding of HB-EGF,
and the other an ADAM17-independent loss of HB-EGF from the
cell surface, possibly through regulated internalization. Second,
the PMA-induced HB-EGF shedding is regulated by at least two
separate pathways, of which one relies on PKCa and the other
involves PKCd and ERK activation.
Using a combination of pharmacological and siRNA-mediated
inhibition, our findings demonstrate that ADAM17 is responsible
for PMA-induced HB-EGF shedding in human HT1080 cells.
This is consistent with several reported studies, showing that
ADAM17 and ADAM10 are the major proteases in shedding of
EGFR-ligands. Specifically, TGFa, HB-EGF, amphiregulin,
epiregulin, and epigen are shed by ADAM17, while ADAM10
appears to be responsible for cleavage of EGF and betacellulin
[7,19,24,27,28]. In addition, ADAM17 is the major PMA-
inducible protease, while ADAM10 is often induced by cellular
Ca
2+ influx [7]. A number of other ADAM proteases, including
ADAM9 and ADAM12, have been implicated in shedding of HB-
EGF, both upon overexpression and in response to PMA [22,29].
However, knockdown of these proteases together with ADAM17
Figure 3. PMA-induced HB-EGF shedding is PKC-dependent. A) AP-HB-EGF release measured as alkaline phosphatase activity (OD 405 nm) in
conditioned media and B) surface AP-HB-EGF measured as cell surface fluorescence intensity per cell (FLU/cell) in DMSO control-treated (C; black
bars) and 30 min PMA-treated (PMA; white bars) AP-HB-EGF expressing HT1080 cells treated with the broad PKC inhibitor BIM1 (2 mM) or vehicle
control. C, D) Representative heat maps of cell surface fluorescence intensity per cell (FLU/cell) in PMA-treated (400 nM, 30 min) AP-HB-EGF
expressing HT1080 cells treated with 1 mM of the InhibitorSelect
TM 96-Well Protein Kinase Inhibitor Library I and II, respectively. Color key and density
plots are shown to the right of the heat maps. All graphs show average values 6 standard error of the mean of at least three independent
experiments each done in triplicate. *p,0.05; **p,0.01, ***p,0.001 after one-way analysis of variance with Bonferroni’s post tests for multiple
comparisons. Unless otherwise indicated, the comparison is relative to the respective control.
doi:10.1371/journal.pone.0017168.g003
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knockdown by itself (data not shown), suggesting that these
proteases cleave HB-EGF-shedding under other circumstances
and possibly in a cell type specific manner. In addition, it cannot
be excluded that matrix metalloproteases abundant in the
HT1080 cells and previously implicated in HB-EGF shedding
(e.g. MMP7 and MT1-MMP) could play a minor role.
While ADAM17 is essential for the PMA-induced shedding of
HB-EGF, ADAM17 inhibition did not entirely prevent the PMA-
induced loss of HB-EGF from the cell surface, raising the question
whether HB-EGF is internalized in response to PMA. Indeed, the
amount of HB-EGF on the cell surface is tightly regulated and it
has been previously suggested that it could be endocytosed after
prolonged treatment with PMA [7]. Moreover, it has been
reported that cholesterol depletion increases the amount of
ADAM-mediated shedding from the cell surface [30,31] and our
preliminary data, showing that cholesterol depletion causes both
increased amounts of HB-EGF on the cell surface and enhanced
shedding, could well be explained by abolished HB-EGF
internalization. Clearly, the model for EGFR-ligand activation
where cytoplasmic synthesis is followed by membrane processing is
too simplified, and does not fully explain HB-EGF’s regulatory
repertoire.
The PMA-induced HB-EGF shedding is well known to depend
on PKC kinase activity [3,18], yet only a few studies have
addressed the issue of the relative contribution of various PKC
isoforms. Screening of kinase inhibitor libraries revealed a number
of PKC inhibitors as potent blockers of PMA-induced HB-EGF-
shedding. Comparing their relative specificity and potency, several
PKC isoforms seem to be involved. Applying siRNA-mediated
knockdown to endogenously expressed PKC isoforms identified
PKCa as a key regulator of ADAM17-dependent shedding,
whereas PKCd and ERK contribute to both constitutive and
stimulated shedding, in what appear to be overlapping mecha-
nisms. Whether the reduction in PMA-induced shedding seen after
PKCd knockdown and MEK inhibition is solely a secondary effect
of the lower amount of available HB-EGF on the cell surface is not
entirely clear. Yet, the combined effect of PKCa knockdown with
either PKCd knockdown or MEK inhibition had a synergistic
effect, completely preventing the stimulated release. Based on
these data, it appears that PKCa acts through a separate pathway
from PKCd and ERK, which on the other hand, seem to function
via overlapping mechanisms. The indication that separate
pathways are activated upon PMA-treatment is further supported
by the observation that a low concentration of PMA is sufficient to
activate PKCa-dependent HB-EGF shedding, whereas high
concentrations are required to engage the input of PKCd.
Comparing our findings to previous reports examining the role
of individual PKC isoforms in ADAM protease activation, PKCa
was found to regulate both basal and PMA-induced N-cadherin
cleavage by ADAM10 [32]. In contrast, PKCd was identified as
the important PKC isoform in ADAM17-mediated shedding of
TNFa in response to high glucose [33] and PMA-induced HB-
EGF-shedding in Vero cells, with no apparent effect of PKCa and
PKCe [22]. Yet, since the latter study used loss of cell surface
expression as an indicator of ectodomain shedding, the observed
effects could reflect changes in transport of HB-EGF to and from
the cell surface rather than ADAM-mediated cleavage.
The involvement of ERK activation in PKC-dependent EGFR-
ligand shedding appears to be highly cell-context dependent. In
some cell systems, ERK activation is a requisite for PMA-induced
shedding of EGFR-ligands [24,34], whereas in this study
inhibition of the MEK-ERK pathways by itself has little effect.
Here, we demonstrate that PMA-treatment results in a rapid
phosphorylation of ERK, which can be completely inhibited by
the MEK inhibitor UO126 as well as the broad PKC inhibitor
BIM1. Yet, siRNA-mediated knockdown of individual endoge-
nously expressed PKC isoforms, including PKCa, PKCd, and
PKCe had no effect on the level of ERK activation, indicating that
other PMA-responsive BIM-sensitive PKC isoforms are involved
or that a degree of redundancy exists. The possibility that the
observed ERK phosphorylation is downstream of EGFR activa-
tion caused by HB-EGF release was ruled out, as knockdown of
ADAM17, leading to a complete block of shedding, had no effect
on PMA-induced ERK activation.
The fact that multiple PKC isoforms play a role in PMA-
induced HB-EGF shedding in HT1080 cells is in line with
previous findings, indicating that PMA-induced shedding of
EGFR-ligands implicates multiple pathways, acting at the level
of both protease and substrate [34,35,36]. PKCs are sophisticated
kinases with multiple activation modes, and despite a high degree
of sequence homology, the PKC isoforms exhibit a significant
degree of non-redundancy, with individual isoforms mediating
unique cellular functions by binding and phosphorylating distinct
protein substrates [37]. While phosphorylation of the cytoplasmic
tail of ADAM17 has been shown to activate its protease activity
[38,39], a truncated form of ADAM17 lacking the entire
intracellular part retains its response to PMA [7,40,41], arguing
Table 1. Inhibitors with a z-score .2 from InhibitorSelect
TM
Library I.
Inhibitor Position AP-HB-EGF release Surface AP-HB-EGF
1 uM 10 uM 1 uM 10 uM
BIM I 11A 24.0 22.9 3.8 4.0
BIM IV 2B 20.9 22.5 0.2 3.8
Go ¨ 6976 7C 24.0 22.6 3.1 2.5
Go ¨ 6983 8C 24.3 22.9 4.7 3.7
PKCb inh. 5F 20.1 22.6 20.4 3.5
Staurosporine 11H 24.2 22.5 3.9 2.3
Staurosporine d. 9F 24.3 22.0 3.0 2.6
Syk inhibitor II 3G 21.7 22.4 20.3 2.6
Average z-score (n=3) (calculated as standard deviations from DMSO-treated
controls on each plate).
doi:10.1371/journal.pone.0017168.t001
Table 2. Inhibitors with a z-score .2 from InhibitorSelect
TM
Library II.
Inhibitor Position AP-HB-EGF release Surface AP-HB-EGF
1 uM 10 uM 1 uM 10 uM
Cdk1/2 Inh. III 8B 1.8 22.4 20.2 2.7
K-252a 4F 24.7 23.8 3.6 3.8
SB218078 4H 23.2 23.5 4.6 4.1
SB220025 6G 20.4 22.8 0.1 3.3
Staurosporine 8H 22.9 23.5 6.5 5.0
Cdk1 Inh. 7B 20.7 22.7 20.1 1.6
Average z-score (n=3) (calculated as standard deviations from DMSO-treated
controls on each plate).
doi:10.1371/journal.pone.0017168.t002
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playing an exclusive role.
The recruitment of specific PKC isoforms to signaling
complexes at the membrane is important for their functions, but
in addition, they control the assembly, disassembly, and
localization of other protein complexes [42]. However, several
lines of evidence indicate that the PMA-induced ADAM17-
mediated HB-EGF cleavage affects only HB-EGF molecules
already present at the cell surface [7], and consistent with this,
we here observed that mainly glycosylated forms of HB-EGF are
shed upon PMA-treatment. Moreover, PMA does not appear to
affect maturation of ADAM17 or its transport to the cell surface
([7] and data not shown). Rather, the key to the PMA-induced
ADAM17 activation may be the induction of conformational
changes in ADAM17 by protein disulfide isomerase as was
strongly suggested in a recent study by Murphy and colleagues
[28]. Thus, how the individual regulatory pathways identified here
converge with mechanisms controlling isomerisation of ADAM17
disulfide-bridges is an intriguing question.
In conclusion, we suggest that PMA-induced ADAM17
activation and subsequent HB-EGF-shedding relies on a PKCa-
dependent signal, which acts cooperatively with a separate
pathway involving PKCd and ERK activity. While PKCa has
no apparent effect on constitutive HB-EGF shedding or the
amount of substrate on the cell surface, PKCd and ERK affect
both constitutive and stimulated shedding by regulating the level of
available HB-EGF on the cell surface. The central role of PKCa is
interesting seen in light of a recent study demonstrating that the
expression of PKCa, but not PKCd and PKCe correlated with
several clinico-pathological parameters in breast cancer patients.
Moreover, in vitro studies demonstrated that PKCa silencing
reduced the proliferation and migration of a human breast cancer
cell-line [43]. Based on these findings, it will be of great interest to
examine whether the reported effect of PKCa on tumour cell
behaviour involves its stimulatory effect on ADAM17, HB-EGF-
shedding, and subsequent EGFR activation, which are all know
drivers in breast cancer progression.
Materials and Methods
Antibodies and reagents
Goat polyclonal antibodies against ADAM17 (clone C-15) and
placental alkaline phosphatase (PLAP, L-19), rabbit polyclonal
antibodies against PKCd (C-17) and PKCe (C-15) were all from
Santa Cruz. Mouse monoclonal anti-PKCa (MC5) hybridoma
media was generated in-house. Mouse monoclonal antibodies
against a-tubulin (B-5-1-2) and PLAP (8B6) were from Sigma,
mouse monoclonal anti-phosphoERK1/2 (Thr202/Tyr204) was
from Cell Signaling, and rabbit polyclonal anti-ERK1/2 was from
UBI. Secondary Alexa FluorH 488-donkey anti-mouse IgG was
from Invitrogen, and horse radish peroxidase (HRP)-conjugated
goat anti-mouse, goat anti-rabbit, and donkey anti-goat were from
Amersham. Phorbol 12-myristate 13-acetate (PMA), the PKC
inhibitor Bisindolylmaleimide I (BIMI), the TACE inhibitor
TAPI-2, and the MEK inhibitor UO126 were from Calbiochem.
The InhibitorSelect
TM 96-well Protein Kinase Inhibitor Library I
and II were from Calbiochem. SigmaFast p-Nitrophenyl phos-
phate tablets and GeneticinH (G-418) were from Sigma.
InterferinH transfection reagent was from PolyPlus, FuGENEH 6
transfection reagent was from Roche Diagnostics, and siGEN-
OME SMARTpool siRNAs were from Dharmacon (Thermo
Fisher).
Cell culture
The human HT1080 fibrosarcoma cell-line was from the
American Type Culture Collection and was cultured in Dulbec-
co’s modified Eagle medium supplemented with 10% fetal bovine
serum, penicillin (50 units/ml) and streptomycin (0.05 mg/ml) in
10% CO2. The cells were transfected with a cDNA construct
encoding pro-HB-EGF fused to alkaline phosphatase (AP) in the
pRC/CMV expression vector (AP-HB-EGF; kindly provided by
Dr. Michael Freeman, Children’s Hospital Boston, MA, USA)
using FuGENE as described by the manufacturer. Forty-eight
hours after transfection, cells were trypsinized and stained for cell-
surface alkaline phosphatase expression, using the mouse mono-
clonal anti-alkaline phosphatase (clone 8B6) ascites fluid and Alexa
FluorH 488-donkey anti-mouse IgG (Invitrogen). The 10%
highest-expressing cells were isolated by FACS and maintained
in culture by selection with 500 mg/ml Geneticin.
Reverse transfection
For gene silencing, HT1080 cells stably expressing AP-HB-EGF
were reverse transfected in 96-well plates. Ten ml siRNAs (375 nM
diluted in Opti-MEMH (Invitrogen)) and 10 ml Interferin trans-
fection reagent diluted in Opti-MEMH (final concentration 0.3 ml/
well) was mixed and incubated at RT for 15–20 min. Eighty mlo f
cells (final concentration of 5610
3 cells/well) in culture medium
Table 3. Specificity of inhibitors identified from InhibitorSelectTM Library I and II.
Inhibitor Specificity
BIM I Broad PKC inhibitor, high selectivity for PKCa;P K C bI+II; PKCc;P K C d;P K C e
BIM IV PKC inhibitor
Go ¨ 6976 PKC inhibitor, high selectivity for classical PKC isozymes
Go ¨ 6983 PKC inhibitor: PKCa; PKCb; PKCc; PKCd; PKCf;P K C i
PKCb inh. PKCb inhibitor, inhibits PKCa; PKCc; PKCe at higher concentrations
Staurosporine Broad kinase inhibitor, potent inhibitor of PKCs
Staurosporine d. Inhibits PKCa;P K C b; PKCc
Syk inhibitor II Syk inhibitor, but inhibits PKCs at higher concentrations
K-252a Staurosporine derivative, inhibits PKCs
SB218078 Inhibits Chk11/12; CDKs
SB220025 p38 MAP kinase 3 inhibitor
doi:10.1371/journal.pone.0017168.t003
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for 3 days.
Shedding assay
HT1080 cells stably expressing AP-HB-EGF were either seeded
in 96-well plates at a concentration of 25000 cells/well and
analyzed for HB-EGF shedding after 24 h or were reverse
transfected with siRNA as described above and used in shedding
assays 72 h later. The confluent cell layer was washed twice with
serum-free medium (SFM) and treated with 400 nM PMA or
DMSO control for 30 min (unless otherwise stated). For treatment
with various chemical inhibitors, 15 min pre-incubation with
inhibitor or the respective vehicle control in SFM was performed
prior to stimulation with or without PMA together with the
respective inhibitors. For photometric quantification of HB-EGF
shedding, cell-conditioned medium was harvested and mixed 1:1
with a 2 mg/ml solution of the alkaline phosphatase substrate 4-
nitrophenyl in 96-well plates. The reactions incubated at 37uC for
1 h in the dark, followed by quantification of alkaline phosphatase
activity by measuring the absorbance at 405 nm. The remaining
cell layer was washed in PBS, and either fixed in 4% formaldehyde
for immuno-fluorescence analysis or lysed directly in 2x sample
buffer for western blot analysis.
Immuno-fluorescence analysis
Cell surface expression of AP-HB-EGF was determined by
immunofluorescent staining. In brief, cells were fixed in 4%
formaldehyde, blocked in 5% bovine serum albumin (BSA) in
phosphate buffered saline (PBS), incubated with primary anti-
PLAP (8B6) diluted 1:1000 in 1% BSA in PBS for 2 hrs at RT,
washed in PBS, incubated with Alexa FluorH 488-donkey anti-
mouse IgG 1:2000 and DAPI (1 ng/ml) in 1% BSA in PBS for 1 hr
at RT, and washed in PBS. For quantification, cells were stained
in black 96-well plates (from Greiner) and the plates were read in
Figure 4. PMA-induced HB-EGF shedding involves cooperative functions of PKCa and PKCd.A ) Western blot analysis of PKCa, PKCd, and
PKCe in total cell extracts from AP-HB-EGF expressing HT1080 cells reverse transfected with control (C) siRNAs or siRNAs against the indicated PKC
isoforms. a-Tubulin is used as an internal loading control. B) AP-HB-EGF release measured as alkaline phosphatase activity (OD 405 nm) in
conditioned media and C) surface AP-HB-EGF measured as cell surface fluorescence intensity per cell (FLU/cell) in DMSO control-treated (C; black
bars) and 30 min PMA-treated (PMA; white bars) in AP-HB-EGF expressing HT1080 cells 72 h after reverse transfection with control (C) siRNAs or
siRNAs against the indicated PKC isoforms. D) Fold PMA-induced change in alkaline phosphatase activity (% of control) in conditioned media from
AP-HB-EGF expressing HT1080 cells treated for 15 or 30 min with either low (25 nM) or high (400 nM) concentrations of PMA, 72 h after reverse
transfection with the indicated siRNAs. All graphs show average values 6 standard error of the mean of at least three independent experiments each
done in triplicate. *p,0.05; **p,0.01, ***p,0.001 after one-way analysis of variance with Bonferroni’s post tests for multiple comparisons. Unless
otherwise indicated, the comparison is relative to the respective control.
doi:10.1371/journal.pone.0017168.g004
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using 405 nm and 488 nm excitation lasers. DAPI and Alexa 488
fluorescence was detected using 405–470 nm and 500–530 nm
bandpass filters, respectively. A sampling resolution of 0.5 mmi n
the X-direction and 7 mm in the Y-direction was used and the
whole well was selected for scanning. To distinguish nuclei from
cellular debris and larger clumps of cells, cell counts were
restricted to objects measuring 5–100 mm in both width and
depth. The total cell number per well was estimated by dividing
the total area of the cells by the average area of a single cell. To
quantify cell-surface expression of Alexa 488 labelled AP-HB-
EGF, the object size was restricted to 7–222 mm in both width and
depth and additional fluorescent parameters including peak, mean
and total intensity measurements were used to gate the population.
Western blot analysis
Cell extracts were separated by SDS-PAGE and transferred to
nitrocellulose membranes (Schleicher and Schuel) according to
standard procedures. Membranes were blocked in 5% nonfat milk,
incubated in primary antibody overnight at 4uC, and developed
Figure 5. PMA-induced HB-EGF shedding acts through at least two separate mechanisms. A) Western blot analysis of phospho-ERK and
total ERK in total cell extracts from AP-HB-EGF expressing HT1080 cells treated with PMA (400 nM, 30 min) or DMSO control and with the MEK
inhibitor UO126 (10 mM), the PKC inhibitior BIM1 (2 mM), or the respective vehicle controls. a-tubulin is used as an internal loading control. B) AP-HB-
EGF release measured as alkaline phosphatase activity (OD 405 nm) in conditioned media from AP-HB-EGF expressing HT1080 cells treated with
400 nM PMA or DMSO control for 30 min and treated with the MEK inhibitor UO126 (10 mM, white bars) or vehicle control (C; black bars). C)a si nB )
except that cells were reverse transfected with control (C) or PKC siRNAs as indicated for 72 h before treatment. D) Western blot analysis of total cell
extracts from cells used in C, demonstrating efficient siRNA-mediated knockdown. a-tubulin is used as an internal loading control. All graphs show
average values 6 standard error of the mean of at least three independent experiments each done in triplicate. *p,0.05; **p,0.01, ***p,0.001 after
one-way analysis of variance with Bonferroni’s post tests for multiple comparisons. Unless otherwise indicated, the comparison is relative to the
respective control.
doi:10.1371/journal.pone.0017168.g005
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bodies and the ECL system (Amersham).
Statistical analysis
Unless otherwise stated, all data represents the average 6
standard error of the mean of at least three independent
experiments each performed in triplicate. The data was analysed
by one-way analysis of variance with Bonferroni’s post test for
multiple comparisons: p,0.05 was considered statistically signif-
icant.
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